Navigation Links
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
Date:6/30/2009

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.

The multi-center, randomized study is anticipated to enroll approximately 120 patients and will compare the efficacy and safety of CXA-101 with the current standard of therapy. The primary efficacy endpoint for this study is microbiological outcome at the test-of-cure visit between six to nine days after the end of therapy.

"The preclinical and Phase 1 results to date are very promising and indicate that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage, including potent activity against increasingly resistant gram-negative pathogens such as Pseudomonas aeruginosa," said Dr. Ian Friedland, chief medical officer of Calixa. "We are going to present comprehensive preclinical and Phase 1 data at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy in September and other medical conferences. This Phase 2 study will generate important information on the safety and effectiveness of CXA-101 in complicated urinary tract infections, which are usually caused by gram-negative pathogens".

Eckard Weber, president and chief executive officer of Calixa and partner at the venture capital firm Domain Associates, LLC said, "With the continually increasing incidence of serious and life-threatening infections caused by resistant gram-negative bacteria and the paucity of new drugs in the pipeline to counter such
'/>"/>

SOURCE Calixa Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
6. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
7. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
8. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
9. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
10. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
11. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... LAVAL, Quebec , July 10, 2014  Valeant ... TSX: VRX) today announced it has completed the sale ... Sculptra, and Dysport owned or held by Valeant for ... agreement with Nestle S.A, which recently completed its acquisition ... complete the divestiture of our products to a company ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... , , , , , SAN ... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and ... ALKS ) today announced positive results from a head-to-head ... BYETTA® (exenatide) injection taken twice daily, in patients with type ...
... , , LONDON, Dec. 14 The 2009 Frost ... Market is conferred on SonoScape. The award recipient has effectively ... pricing, and portability - and introduced the S8 hand-carried ultrasound ... compares with that of a regular, high-end, cart-based echo ultrasound ...
Cached Medicine Technology:Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 2Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 3
(Date:7/10/2014)... 10, 2014 One week ahead of ... Safety announced today it will extend compensation benefits to ... wages for workers displaced as a result of factory ... inspections have resulted in the closure of five factories ... cases, raising immediate safety concerns. In May, the Alliance—in ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... A new study from Colorado School of Public ... health remains a major problem in the Navajo Nation ... among Native Americans is abysmal with more than three ... said Terrence Batliner, DDS, MBA, associate director of the ... of Public Health. "The number one problem is access ...
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... survey which was conducted in Delhi, Mumbai, Chennai, Hyderabad and Kolkata ... of the harmful effects of ultra-violet (UV) rays. // The results ... that UV rays affect the eyes. About 73% of the people ... also found that people do not take any precaution to protect ...
... Minister Manmohan Singh underwent a minor surgical procedure on his ... this morning. // ,'The operation on the left ... October 13, 2005. This completes the procedure advised by doctors ... Prime Minister's media advisor Sanjaya Baru said in a statement., ...
... immolation at the Ramlila grounds in New Delhi at a ... // The student had 15 percent burns and was admitted ... Delhi and Kanpur are to go at a hunger strike ... Union Health Ministry has issued orders to nine central medical ...
... from high blood pressure, heart disease and a number ... arteries // , overactive thyroid gland not to take ... there is an increase in the number of cases ... also asked the patients to consult their doctors before ...
... over the past three years has found that increasingly stress ... of the people. // More than 50 percent of the ... condition that increases the risk of heart attack and stroke, ... the people in the age group of 40-70 years were ...
... study conducted by Readers Digest Magazine for a poll it ... and psychic powers. // About 50% of them said that ... surveyed about 1,006 adults and 43% said that they could ... expert. About 50% said that they had dreamt of an ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: